Lilly Q2: Strong Top-Line, But Momentum Needs Confirmation - Tactical Long Setup
Eli Lilly delivered a robust Q2 with revenue near $23B and hefty profit beats driven by Mounjaro and Zepbound. The market has already priced much of that success - valuation sits near 40x earnings and momentum indicators have cooled. This is an actionable tactical long: enter at current levels, target the 52-week high, and use a stop below the 50-d…